Advanced bladder cancer: Status of first-line chemotherapy and the search for active agents in the second-line setting Journal Article
| Authors: | Gallagher, D. J.; Milowsky, M. I.; Bajorin, D. F. |
| Article Title: | Advanced bladder cancer: Status of first-line chemotherapy and the search for active agents in the second-line setting |
| Abstract: | Urothelial carcinoma (IJQ remains a significant health problem affecting an estimated 68,810 people in 2008 alone in the US. The majority of patients with metastatic disease develop disease recurrence, and long-term survival rates are poor. There is no standard of care for the treatment of patients with UC after the failure of cisplatin-based regimens in the first-line setting. Efforts to improve second-line treatment have led to the evaluation of single agents such as vinflunine and pemetrexed, and multidrug combinations with cytotoxic and targeted agents, including trastuzumab and bevacizumab. The authors reviewed the activity of several single agents and combination regimens in patients with UC. Emerging strategies for the measurement of response in clinical trials were also outlined. © 2008 American Cancer Society. |
| Keywords: | cancer chemotherapy; cancer survival; treatment response; overall survival; clinical trial; constipation; disease course; fatigue; neutropenia; paresthesia; review; salvage therapy; sorafenib; bevacizumab; cisplatin; doxorubicin; fluorouracil; sunitinib; advanced cancer; drug dose reduction; drug efficacy; gastrointestinal hemorrhage; gemcitabine; paclitaxel; methotrexate; topotecan; positron emission tomography; gastrointestinal stromal tumor; carboplatin; unindexed drug; bortezomib; multiple cycle treatment; sensory neuropathy; neoplasm recurrence, local; anemia; bone marrow suppression; mucosa inflammation; thrombocytopenia; antineoplastic combined chemotherapy protocols; cyclophosphamide; vincristine; continuous infusion; bladder cancer; urinary bladder neoplasms; ifosfamide; vinblastine; docetaxel; irinotecan; febrile neutropenia; confidence interval; survival time; folinic acid; gefitinib; urothelial carcinoma; nausea and vomiting; sepsis; world health organization; kidney cancer; trastuzumab; navelbine; oxaliplatin; pemetrexed; lapatinib; ixabepilone; vinflunine; kidney dysfunction; second-line; transitional cell carcinoma of the urothelium; 2 (2 dimethylaminoethyl) 9 methoxy 5 nitropyrazolo[3,4,5 kl]acridine; piritrexim |
| Journal Title: | Cancer |
| Volume: | 113 |
| Issue: | 6 |
| ISSN: | 0008-543X |
| Publisher: | Wiley Blackwell |
| Date Published: | 2008-09-15 |
| Start Page: | 1284 |
| End Page: | 1293 |
| Language: | English |
| DOI: | 10.1002/cncr.23692 |
| PUBMED: | 18629841 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | --- - "Cited By (since 1996): 28" - "Export Date: 17 November 2011" - "CODEN: CANCA" - "Source: Scopus" |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work